Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 13 studies | 30% ± 13% | |
peripheral blood | 9 studies | 28% ± 11% | |
eye | 7 studies | 27% ± 10% | |
intestine | 6 studies | 25% ± 12% | |
kidney | 5 studies | 21% ± 3% | |
liver | 5 studies | 26% ± 15% | |
uterus | 4 studies | 31% ± 17% | |
lymph node | 4 studies | 24% ± 10% | |
breast | 4 studies | 21% ± 4% | |
brain | 4 studies | 27% ± 10% | |
pancreas | 3 studies | 33% ± 21% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2014.77 | 1445 / 1445 | 100% | 27.70 | 183 / 183 |
ovary | 100% | 1566.33 | 180 / 180 | 100% | 43.08 | 430 / 430 |
brain | 100% | 2508.02 | 2639 / 2642 | 100% | 48.67 | 705 / 705 |
thymus | 100% | 1841.24 | 653 / 653 | 100% | 46.02 | 603 / 605 |
stomach | 100% | 1639.72 | 359 / 359 | 99% | 37.45 | 284 / 286 |
prostate | 100% | 1898.04 | 245 / 245 | 99% | 50.10 | 498 / 502 |
intestine | 100% | 1968.74 | 966 / 966 | 99% | 43.08 | 522 / 527 |
pancreas | 100% | 1226.48 | 328 / 328 | 99% | 32.10 | 176 / 178 |
uterus | 100% | 1785.15 | 170 / 170 | 99% | 34.74 | 453 / 459 |
kidney | 100% | 1803.06 | 89 / 89 | 99% | 33.83 | 889 / 901 |
skin | 100% | 2503.10 | 1808 / 1809 | 99% | 50.20 | 465 / 472 |
adrenal gland | 100% | 2640.43 | 258 / 258 | 98% | 53.30 | 226 / 230 |
lung | 100% | 1638.62 | 576 / 578 | 98% | 31.63 | 1135 / 1155 |
liver | 100% | 1057.79 | 226 / 226 | 98% | 26.01 | 396 / 406 |
bladder | 100% | 1908.38 | 21 / 21 | 97% | 35.86 | 491 / 504 |
breast | 100% | 1910.10 | 459 / 459 | 97% | 38.41 | 1086 / 1118 |
adipose | 100% | 1906.22 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 51.32 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 38.83 | 29 / 29 |
muscle | 100% | 2782.41 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 1663.73 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 33.63 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 21.20 | 1 / 1 |
blood vessel | 100% | 2157.78 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 98% | 1737.37 | 844 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 96% | 957.73 | 891 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0006281 | Biological process | DNA repair |
GO_0002931 | Biological process | response to ischemia |
GO_0000209 | Biological process | protein polyubiquitination |
GO_0030512 | Biological process | negative regulation of transforming growth factor beta receptor signaling pathway |
GO_0034605 | Biological process | cellular response to heat |
GO_0000165 | Biological process | MAPK cascade |
GO_0045862 | Biological process | positive regulation of proteolysis |
GO_0032436 | Biological process | positive regulation of proteasomal ubiquitin-dependent protein catabolic process |
GO_0071456 | Biological process | cellular response to hypoxia |
GO_0051865 | Biological process | protein autoubiquitination |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0071218 | Biological process | cellular response to misfolded protein |
GO_0031943 | Biological process | regulation of glucocorticoid metabolic process |
GO_0034392 | Biological process | negative regulation of smooth muscle cell apoptotic process |
GO_0034393 | Biological process | positive regulation of smooth muscle cell apoptotic process |
GO_0090035 | Biological process | positive regulation of chaperone-mediated protein complex assembly |
GO_0030968 | Biological process | endoplasmic reticulum unfolded protein response |
GO_0038128 | Biological process | ERBB2 signaling pathway |
GO_0006515 | Biological process | protein quality control for misfolded or incompletely synthesized proteins |
GO_0061684 | Biological process | chaperone-mediated autophagy |
GO_0050821 | Biological process | protein stabilization |
GO_0070534 | Biological process | protein K63-linked ubiquitination |
GO_1901526 | Biological process | positive regulation of mitophagy |
GO_0031398 | Biological process | positive regulation of protein ubiquitination |
GO_1904294 | Biological process | positive regulation of ERAD pathway |
GO_0006513 | Biological process | protein monoubiquitination |
GO_0036503 | Biological process | ERAD pathway |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0031647 | Biological process | regulation of protein stability |
GO_0051604 | Biological process | protein maturation |
GO_0042405 | Cellular component | nuclear inclusion body |
GO_0000151 | Cellular component | ubiquitin ligase complex |
GO_0030018 | Cellular component | Z disc |
GO_0005739 | Cellular component | mitochondrion |
GO_0005654 | Cellular component | nucleoplasm |
GO_0101031 | Cellular component | protein folding chaperone complex |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005829 | Cellular component | cytosol |
GO_0031371 | Cellular component | ubiquitin conjugating enzyme complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0019899 | Molecular function | enzyme binding |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0070412 | Molecular function | R-SMAD binding |
GO_0030911 | Molecular function | TPR domain binding |
GO_0051787 | Molecular function | misfolded protein binding |
GO_0051879 | Molecular function | Hsp90 protein binding |
GO_0019900 | Molecular function | kinase binding |
GO_0034450 | Molecular function | ubiquitin-ubiquitin ligase activity |
GO_0031072 | Molecular function | heat shock protein binding |
GO_0046332 | Molecular function | SMAD binding |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0001664 | Molecular function | G protein-coupled receptor binding |
GO_0051087 | Molecular function | protein-folding chaperone binding |
GO_0030674 | Molecular function | protein-macromolecule adaptor activity |
GO_0030544 | Molecular function | Hsp70 protein binding |
GO_0048156 | Molecular function | tau protein binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | STUB1 |
Protein name | RING-type E3 ubiquitin transferase (EC 2.3.2.27) E3 ubiquitin-protein ligase CHIP (EC 2.3.2.27) (Antigen NY-CO-7) (CLL-associated antigen KW-8) (Carboxy terminus of Hsp70-interacting protein) (RING-type E3 ubiquitin transferase CHIP) (STIP1 homology and U box-containing protein 1) STIP1 homology and U-box containing protein 1 |
Synonyms | CHIP PP1131 |
Description | FUNCTION: E3 ubiquitin-protein ligase which targets misfolded chaperone substrates towards proteasomal degradation . Plays a role in the maintenance of mitochondrial morphology and promotes mitophagic removal of dysfunctional mitochondria; thereby acts as a protector against apoptosis in response to cellular stress (By similarity). Negatively regulates vascular smooth muscle contraction, via degradation of the transcriptional activator MYOCD and subsequent loss of transcription of genes involved in vascular smooth muscle contraction (By similarity). Promotes survival and proliferation of cardiac smooth muscle cells via ubiquitination and degradation of FOXO1, resulting in subsequent repression of FOXO1-mediated transcription of pro-apoptotic genes . Ubiquitinates ICER-type isoforms of CREM and targets them for proteasomal degradation, thereby acts as a positive effector of MAPK/ERK-mediated inhibition of apoptosis in cardiomyocytes . Inhibits lipopolysaccharide-induced apoptosis and hypertrophy in cardiomyocytes, via ubiquitination and subsequent proteasomal degradation of NFATC3 . Collaborates with ATXN3 in the degradation of misfolded chaperone substrates: ATXN3 restricting the length of ubiquitin chain attached to STUB1/CHIP substrates and preventing further chain extension . Ubiquitinates NOS1 in concert with Hsp70 and Hsp40 . Modulates the activity of several chaperone complexes, including Hsp70, Hsc70 and Hsp90 . Ubiquitinates CHRNA3 targeting it for endoplasmic reticulum-associated degradation in cortical neurons, as part of the STUB1-VCP-UBXN2A complex . Ubiquitinates and promotes ESR1 proteasomal degradation in response to age-related circulating estradiol (17-beta-estradiol/E2) decline, thereby promotes neuronal apoptosis in response to ischemic reperfusion injury (By similarity). Mediates transfer of non-canonical short ubiquitin chains to HSPA8 that have no effect on HSPA8 degradation . Mediates polyubiquitination of DNA polymerase beta (POLB) at 'Lys-41', 'Lys-61' and 'Lys-81', thereby playing a role in base-excision repair: catalyzes polyubiquitination by amplifying the HUWE1/ARF-BP1-dependent monoubiquitination and leading to POLB-degradation by the proteasome . Mediates polyubiquitination of CYP3A4 . Ubiquitinates EPHA2 and may regulate the receptor stability and activity through proteasomal degradation . Acts as a co-chaperone for HSPA1A and HSPA1B chaperone proteins and promotes ubiquitin-mediated protein degradation . Negatively regulates the suppressive function of regulatory T-cells (Treg) during inflammation by mediating the ubiquitination and degradation of FOXP3 in a HSPA1A/B-dependent manner . Catalyzes monoubiquitination of SIRT6, preventing its degradation by the proteasome . Likely mediates polyubiquitination and down-regulates plasma membrane expression of PD-L1/CD274, an immune inhibitory ligand critical for immune tolerance to self and antitumor immunity . Negatively regulates TGF-beta signaling by modulating the basal level of SMAD3 via ubiquitin-mediated degradation . Plays a role in the degradation of TP53 . Mediates ubiquitination of RIPK3 leading to its subsequent proteasome-dependent degradation . May regulate myosin assembly in striated muscles together with UBE4B and VCP/p97 by targeting myosin chaperone UNC45B for proteasomal degradation . . |
Accessions | ENST00000219548.9 [Q9UNE7-1] H3BS86 Q9UNE7 ENST00000564316.1 V9GYH3 H3BTA3 H3BUD0 ENST00000566408.5 ENST00000564370.5 [Q9UNE7-2] ENST00000565677.5 [Q9UNE7-2] ENST00000565813.1 ENST00000567173.5 |